An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Zomagen Biosciences Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06836232
- Locations
- ๐บ๐ธ
Local Site #840012, Tucson, Arizona, United States
๐บ๐ธLocal Site #840016, St. Augustine, Florida, United States
๐บ๐ธLocal Site #840008, Chicago, Illinois, United States
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Phase 2
Recruiting
- Conditions
- Obesity
- Interventions
- Drug: VTX3232 Dose ADrug: Placebo in combination with semaglutideDrug: PlaceboDrug: VTX3232 Dose A in combination with semaglutide
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Zomagen Biosciences Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06771115
- Locations
- ๐บ๐ธ
840005, Birmingham, Alabama, United States
๐บ๐ธ840001, Largo, Florida, United States
๐บ๐ธ840012, Ocoee, Florida, United States
Phase 2a Study of VTX3232 in Parkinson's Disease
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Zomagen Biosciences Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06556173
- Locations
- ๐บ๐ธ
Local Site #840001, New Haven, Connecticut, United States
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Zomagen Biosciences Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT05812781
- Locations
- ๐บ๐ธ
Local Site # 222, San Diego, California, United States
๐บ๐ธLocal Site # 223, Columbus, Georgia, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath